Gene Therapy Targeting p53 and KRAS for Colorectal Cancer Treatment: A Myth or the Way Forward?

Autor:	Marahaini Musa, Hidayati Husainy Hasbullah
Rok vydání:	2021
Předmět:	p53 Oncology medicine.medical_specialty Tumor suppressor gene QH301-705.5 Colorectal cancer medicine.medical_treatment Genetic enhancement Review Disease medicine.disease_cause Malignancy Catalysis Targeted therapy Proto-Oncogene Proteins p21(ras) Inorganic Chemistry Internal medicine KRAS medicine Humans Biology (General) Physical and Theoretical Chemistry QD1-999 neoplasms Molecular Biology Spectroscopy business.industry Organic Chemistry Cancer Genetic Therapy General Medicine targeted therapy medicine.disease digestive system diseases Computer Science Applications Chemistry colon cancer Mutation Tumor Suppressor Protein p53 Colorectal Neoplasms business
Zdroj:	International Journal of Molecular Sciences, Vol 22, Iss 11941, p 11941 (2021) International Journal of Molecular Sciences
ISSN:	1422-0067
Popis:	Colorectal cancer (CRC) is the third most commonly diagnosed malignancy worldwide and is responsible as one of the main causes of mortality in both men and women. Despite massive efforts to raise public awareness on early screening and significant advancements in the treatment for CRC, the majority of cases are still being diagnosed at the advanced stage. This contributes to low survivability due to this cancer. CRC patients present various genetic changes and epigenetic modifications. The most common genetic alterations associated with CRC are p53 and KRAS mutations. Gene therapy targeting defect genes such as TP53 (tumor suppressor gene encodes for p53) and KRAS (oncogene) in CRC potentially serves as an alternative treatment avenue for the disease in addition to the standard therapy. For the last decade, significant developments have been seen in gene therapy for translational purposes in treating various cancers. This includes the development of vectors as delivery vehicles. Despite the optimism revolving around targeted gene therapy for cancer treatment, it also has various limitations, such as a lack of availability of related technology, high cost of the involved procedures, and ethical issues. This article will provide a review on the potentials and challenges of gene therapy targeting p53 and KRAS for the treatment of CRC.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f0c7f73d8db4b288ccbae3c65f34ce5 https://doi.org/10.3390/ijms222111941 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.